GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shionogi & Co Ltd (TSE:4507) » Definitions » Total Liabilities

Shionogi (TSE:4507) Total Liabilities : 円164,357 Mil (As of Mar. 2024)


View and export this data going back to 1949. Start your Free Trial

What is Shionogi Total Liabilities?

Shionogi's Total Liabilities for the quarter that ended in Mar. 2024 was 円164,357 Mil.

Shionogi's quarterly Total Liabilities declined from Sep. 2023 (円178,161.00 Mil) to Dec. 2023 (円145,522.00 Mil) but then increased from Dec. 2023 (円145,522.00 Mil) to Mar. 2024 (円164,357.00 Mil).

Shionogi's annual Total Liabilities increased from Mar. 2022 (円157,316.00 Mil) to Mar. 2023 (円189,922.00 Mil) but then declined from Mar. 2023 (円189,922.00 Mil) to Mar. 2024 (円164,357.00 Mil).


Shionogi Total Liabilities Historical Data

The historical data trend for Shionogi's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shionogi Total Liabilities Chart

Shionogi Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 108,492.00 134,442.00 157,316.00 189,922.00 164,357.00

Shionogi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 189,922.00 171,598.00 178,161.00 145,522.00 164,357.00

Shionogi Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Shionogi's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=133907+(8753+13703
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+7994)
=164,357

Total Liabilities=Total Assets (A: Mar. 2024 )-Total Equity (A: Mar. 2024 )
=1416918-1252561
=164,357

Shionogi's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=133907+(8753+13703
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+7994)
=164,357

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=1416918-1252561
=164,357

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shionogi Total Liabilities Related Terms

Thank you for viewing the detailed overview of Shionogi's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Shionogi (TSE:4507) Business Description

Traded in Other Exchanges
Address
1-8, Doshomachi 3-chome, Chuo-ku, Osaka, JPN, 541-0045
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Shionogi (TSE:4507) Headlines

No Headlines